首页期刊导航|Headache
期刊信息/Journal information
Headache
Blackwell Publishing, Inc
Headache

Blackwell Publishing, Inc

0017-8748

Headache/Journal HeadacheSCIISTPAHCIBSCI
正式出版
收录年代

    Worsening migraine: Another casualty of natural disasters

    Amy A. GelfandRashmi B. Halker SinghMatthew S. Robbins
    3页

    Twenty twenty … two: Headache and COVID‐19

    Edoardo CaronnaPatricia Pozo‐Rosich
    2页

    Headache associated with COVID‐19: Epidemiology, characteristics, pathophysiology, and management

    Pedro Augusto Sampaio Rocha‐Filho
    7页
    查看更多>>摘要:Abstract Objective To review data regarding the epidemiology, pathophysiology, characteristics, and management of COVID‐19–associated headache. The persistence of headache after the acute phase of COVID‐19 was also reviewed. Background Headache is a frequent symptom of COVID‐19, and understanding its management is important for health‐care professionals involved in treating the disease. Method This is a narrative review. A literature review was conducted in the PubMed database with the following terms: “headache” and “COVID‐19.” All articles written in English that were considered relevant were included. Results Half of the patients who have COVID‐19 present with headache, which occurs more frequently in younger patients; in those with previous primary headache or with previous migraine; and in those who have concomitantly presented with anosmia, ageusia, and myalgia. The headache usually begins early in the symptomatic phase, is bilateral, moderate to severe, and has a similar pattern to tension‐type headache. All studies found the migraine pattern and the tension‐type headache pattern to be frequent patterns. The possible pathophysiological mechanisms include direct viral injury, the inflammatory process, hypoxemia, coagulopathy, and endothelial involvement. Common analgesics and nonsteroidal anti‐inflammatory drugs are the most commonly used drugs for headache in the acute phase of COVID‐19. The headache may persist beyond the acute phase, and in such cases, there is an improvement over time. However, not all patients’ headaches improve. It seems to be a greater proportion of patients whose headache improves in the first 3?months after the acute phase of the disease than after this period. COVID‐19?may trigger new daily persistent headache. Conclusions Headache is a clinically significant symptom of COVID‐19. Although its characteristics in the acute phase of the disease are already well known, there is a need for studies on its management and persistence.

    Impact of the 2018 Japan Floods on prescriptions for migraine: A longitudinal analysis using the National Database of Health Insurance Claims

    Yuji OkazakiShuhei YoshidaSaori KashimaSoichi Koike...
    11页
    查看更多>>摘要:Abstract Objective To determine the impact of the 2018?Japan Floods, one of the largest water disasters in Japan, on the number of prescriptions for triptans and ergotamine (acute treatment). Background Natural disasters frequently occur worldwide and may cause psychological stress–related diseases. Acute migraine attacks can be triggered by psychological stress. Disaster victims are likely to experience tremendous psychological stress; however, the relationship between natural disasters and migraine attacks is not well investigated. Methods A retrospective longitudinal cohort study was conducted using the National Database of Health Insurance Claims in the hardest‐hit areas of the disaster 1?year before and after the disaster. We included people between the ages of 15 and 64 years. Those who had a victim code that was certificated by a local government were assigned to the victim group, and others to the nonvictim group. For those who were not prescribed acute treatment before the disaster (i.e., group without previous acute treatment), the cumulative incidence of new prescriptions for acute treatment at 12?months of follow‐up was calculated and compared between victims and nonvictims with survival analysis. Results Of 3,475,515 people aged 15 to 64?years enrolled in the study, 16,103 (0.46%) were assigned to the victim group. In the group without previous acute treatment, 111 (0.70%) of 15,933 victims and 14,626 (0.43%) of 3,431,423 nonvictims were newly prescribed acute treatment after the disaster, and new prescriptions for acute treatment were significantly more likely to occur in victims than in nonvictims (adjusted hazard ratio, 1.68; 95% CI, 1.39–2.02). Conclusions The 2018?Japan Floods increased the number of prescriptions for acute migraine medications among victims, suggesting that acute migraine attacks occurred more frequently after a natural disaster.

    New insight into the neural mechanisms of migraine in adolescents: Relationships with sleep

    Hadas Nahman‐AverbuchVictor J. SchneiderGregory R. LeeJames L. Peugh...
    13页
    查看更多>>摘要:Abstract Objective This case‐control study examines if measures of subjective and objective (actigraphic) sleep difficulties mediate alterations in amygdalar connectivity in adolescents with migraine compared to healthy adolescents. Background Adolescents with migraine have different functional connectivity of the amygdala compared to individuals without migraine. Sleep is often disturbed in adolescents with migraine, and could contribute to the alterations in functional connectivity. Methods Twenty adolescents with migraine and 20?healthy controls were recruited from Cincinnati Children’s Hospital. Participants completed surveys about their headaches and overall sleep quality, sleep hygiene, and perceived sleep difficulties (Insomnia Severity Scale [ISI]); completed wrist‐worn actigraphy; and underwent a magnetic resonance imaging scan. Results Adolescents with migraine differed from healthy controls only in perceived difficulty in sleep initiation and maintenance (ISI: 8.5?±?4.7 and 4.5?±?3.7 [mean?±?standard deviation], ?4.00 [95% confidence: ?6.7 to ?1.3], p?=?0.005) and had greater functional connectivity between the amygdala and the posterior cingulate cortex, precuneus, dorsolateral prefrontal, sensorimotor, and the occipital cortexes. The differences in functional connectivity of the amygdala were not mediated by the subjective/objective sleep measures (ISI/wake minutes after sleep onset). Conclusions Adolescents with migraine have greater connectivity between the amygdala and areas involved in sensory, affective, and cognitive aspects of pain. These alterations may not be due to higher levels of sleep difficulties in adolescents with migraine, suggesting that both amygdala and sleep alterations may play an independent role in migraine pathophysiology. This advances the understanding of the mechanisms underlying pediatric migraine and can potentially advance migraine management.

    A randomized trial of ketorolac and metoclopramide for migraine in the emergency department

    Lawrence P. RicherSamina AliDavid W. JohnsonRhonda?J. Rosychuk...
    9页
    查看更多>>摘要:Abstract Objective The objective of this study was to assess the efficacy and safety of a common monotherapy (intravenous [iv] metoclopramide) compared to a combination strategy (adding iv ketorolac to metoclopramide) in children presenting for acute treatment of migraine headache in the emergency department (ED). Methods Children aged 5–17?years presenting for acute treatment of migraine headache at two pediatric EDs were enrolled in a double‐blind randomized controlled trial. Children were randomly assigned to receive iv metoclopramide 0.2?mg/kg) and placebo or iv metoclopramide (0.2?mg/kg) and ketorolac (0.5?mg/kg). The primary outcome was a mean change in pain from baseline to 120?min via a 100?mm Visual Analog Scale (VAS). Follow‐up was conducted 24‐h after discharge. Results Fifty‐three children were randomized and included in the analysis (monotherapy group [metoclopramide + placebo], n?=?27; and ketorolac group [metoclopramide + ketorolac], n?=?26); mean age was 12.9?±?2.7?years and baseline pain severity on VAS was 67.3?±?2.7?mm. The mean change in pain intensity at 120?min was ?44?mm (SD: 24; 95% confidence interval [CI]: 32–57) for the monotherapy group and ?36?mm (SD: 24; 95% CI: 23–49) for the ketorolac group, with a mean difference between groups of 8?mm (95% CI: ?9–25; p?=?0.360). Seventeen percent of the children (9/53; 95% CI: 7–27%) were pain‐free at discharge. There was no difference in headache recurrence or adverse events between groups. Conclusions The approach of combining iv metoclopramide with ketorolac failed to improve pain scores in children presenting for acute treatment of migraine headache in the ED compared to metoclopramide monotherapy. Most patients were discharged with residual pain. Further comparative studies are needed to test alternative ED treatments for migraine in children or adolescents.

    Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention

    Richard B. LiptonPeter J. GoadsbyDavid W. DodickJames S. McGinley...
    10页
    查看更多>>摘要:Abstract Objective To assess the utility of the novel patient‐identified (PI) most bothersome symptom (MBS) measure from PROMISE‐2, a phase 3 trial of eptinezumab for the preventive treatment of chronic migraine. Background Relief of bothersome migraine symptoms can influence satisfaction with treatment and therapeutic persistence. Understanding the impact of preventive treatment on a PI‐MBS could improve clinical decision‐making. Methods In PROMISE‐2, patients with chronic migraine received eptinezumab 100, 300?mg, or placebo administered intravenously every 12?weeks for up to 2 doses (n?=?1072). PI‐MBS was an exploratory outcome requiring each patient to self‐report their MBS in response to an open‐ended question. At baseline and week 12, patients rated overall improvement in PI‐MBS. The relationships among PI‐MBS at week 12 and change in monthly migraine days (MMDs) from baseline to month 3 (weeks 9–12), Patient Global Impression of Change at week 12, and changes from baseline to week 12 in the 6‐item Headache Impact Test total, EuroQol 5‐dimensions 5‐levels visual analog scale, and 36‐item Short‐Form Health Survey component scores were assessed. Results Treatment groups had similar baseline characteristics and reported a total of 23 unique PI‐MBS, most commonly light sensitivity (200/1072, 18.7%), nausea/vomiting (162/1072, 15.1%), and pain with activity (147/1072, 13.7%). Improvements in PI‐MBS at week 12 correlated with changes in MMDs (ρ?=??0.49; p?<?0.0001) and other patient‐reported outcomes. Controlling for changes in MMDs, PI‐MBS improvement predicted other patient‐reported outcomes in expected directions. The magnitude of the standardized mean differences between placebo and active treatment for PI‐MBS were 0.31 (p?<?0.0001 vs. placebo) and 0.54 (p?<?0.0001 vs. placebo) for eptinezumab 100 and 300?mg, respectively. Conclusions Improvement in PI‐MBS at week 12 was associated with improvement in other patient‐reported outcome measures, and PI‐MBS may be an important patient‐centered measure of treatment benefits in patients with chronic migraine.

    Persistence of headache and its relation to other major sequelae following traumatic brain injury at 2–8?years after deployment‐related traumatic brain injury in veterans of Afghanistan and Iraq wars

    James R. CouchKenneth E. Stewart
    18页
    查看更多>>摘要:Abstract Objective This study deals with headache in relation to other major sequelae of traumatic brain injury (TBI) in veterans of Iraq and Afghanistan wars over 8?years after experiencing a deployment‐related TBI (DTBI). Background TBI occurred in 14%–23% of veterans deployed to the Iraq or Afghanistan campaigns. This study evaluates sequelae of TBI (STBI) over 1–8?years after a DTBI. Methods This is a secondary, cross‐sectional analysis of previously collected data, which was taken from review of medical records of the first 500 veterans with a DTBI seen in the TBI clinic of the Oklahoma City Veterans Health Center. This report deals with five of the most common STBIs and represents the presence and severity of, or absence of, the particular symptom at the time of a patient’s initial visit to the clinic. All subjects were evaluated between June 1, 2008, and April 30, 2011. The STBI used here include: headache, dizziness, balance, coordination difficulties, and difficulty with decisions. In the TBI clinic, the burden of these symptoms was evaluated with a Likert Scale of none, mild, moderate, severe, or very severe. For this report, the scale was compressed into three categories: none, mild/moderate, and severe/very severe. Data were complete for age at TBI and mechanism of TBI in 500 subjects, for symptom severity in 497 subjects, for TBI severity in 491 subjects, and for presence of prior TBI in 496 subjects. Results For the 497 subjects with complete symptom severity data, headache was seen in 476 (95.8%) and absent in 21 (4.2%). Regarding headache severity, 236 (47.5%) reported mild/moderate and 240 (48.3%) reported severe/very severe headache burden. For other sequelae, including severity of dizziness, balance, and coordination problems, these symptoms were absent in 85 (17.1%), 85 (17.1%), and 106 (21.3%) patients, respectively; of mild/moderate severity in 356 (71.6%), 355 (71.4%), and 321 (64.6%) patients; and of severe/very severe intensity in 56 (11.3%), 57 (11.5%), and 70 (14.1%) patients. Difficulty with decisions, which was used as an indication of cognitive difficulty, was noted in 429 (86.3%) of the subjects, of which 252 (50.7%) noted mild/moderate and 177 (35.6%) severe/very severe intensity. To evaluate changes over time, the subjects were divided into 2‐year cohorts of 1–2, 3–4, 5–6, and 7–8?years since DTBI. Comparing symptom burden within these four 2‐year cohorts, there was no statistically significant change in symptom burden analyzing by time interval from DTBI to TBI clinic evaluation. For analysis by severity of the DTBI in 491 subjects with complete data, categories were constructed based on alteration of consciousness (AOC) or duration of loss of consciousness (LOC) as follows: AOC (264/491 [53.8%]); LOC <1?min (95/491 [19.4%]); LOC, 1–30?min (115/491 [23.4%]); and LOC >30?min (17/491 [3.5%]). The proportion of subjects with severe/very severe symptom intensity increased as the severity of the DTBI increased (from p?=?0.043 to p?=?0.001). Additional evaluations included groupings by age at DTBI (20–29, 30–39, and ≥40?years), by presence or absence of a TBI prior to the DTBI, and by causation of the DTBI (blast or direct head trauma). No significant differences were observed with any of these comparisons. Conclusion For veterans experiencing a DTBI, these TBI‐related sequelae persist with little improvement over time up to 8?years. A trend toward symptoms becoming worse as DTBI severity increased was observed. Headache was the most frequent sequela of TBI, occurring in 96% of the patients with almost half of these reporting severe/very severe intensity of headache burden. The basis for the prolonged persistence of these STBI is not known.

    Normal glymphatic system function in patients with migraine: A pilot study

    Dong Ah LeeHo‐Joon LeeKang Min Park
    8页
    查看更多>>摘要:Abstract Objective No studies have evaluated the glymphatic system function in patients with migraine. In this pilot study, we evaluated and compared the alterations in the glymphatic system function in patients with migraine with healthy controls using a diffusion tensor imaging (DTI) analysis along the perivascular space (DTI‐ALPS) method. We also investigated the differences in the glymphatic system function table between patients with migraine with and without aura using the ALPS method. Methods This field study used a cross‐sectional study design. We prospectively enrolled patients with migraine and healthy controls. All brain magnetic resonance imaging (MRI), including DTI, in participants, patients with migraine, and healthy controls were obtained using the same MRI scanner. We calculated and compared the ALPS index between patients with migraine and healthy controls, and between patients with migraine with and without aura. In addition, we investigated the association between the glymphatic system function and the clinical characteristics of migraine. Results We enrolled 92 patients with migraine and 80?healthy controls. There were no significant differences in the ALPS index between patients with migraine and healthy controls (1.655?±?0.335 [patients with migraine] vs. 1.713?±?0.297 [controls], difference = 0.058, 95% confidence interval [CI] of difference = ?0.037 to 0.154, p?=?0.233), and between patients with migraine with and without aura (1.690?±?0.380 [with aura] vs. 1.645?±?0.323 [without aura], difference = ?0.044, 95% CI of difference = ?0.213 to 0.124, p?=?0.601). There was no significant correlation between the ALPS index and clinical characteristics of migraine, including age (r = ?0.07, p?=?0.507), age at onset (r?=?0.07, p?=?0.552), disease duration (r = ?0.12, p?=?0.306), attack frequency (r = ?0.05, p?=?0.668), and headache intensity (r?=?0.00, p?=?0.976). Conclusions There was no glymphatic system dysfunction in patients with migraine. Moreover, there were no differences in the glymphatic system function between patients with migraine with and without aura. We also demonstrated the feasibility of the ALPS method, which can be used for research on various neurological diseases. Further studies are needed to confirm our findings.

    Cutaneous heat and light‐induced pain thresholds in post‐traumatic headache attributed to mild traumatic brain injury

    Amaal J. StarlingMelissa M. CortezNicholas R. JarvisNan Zhang...
    11页
    查看更多>>摘要:Abstract Objective The purpose of this study was to characterize cutaneous heat and light‐induced pain thresholds in people with post‐traumatic headache (PTH) compared with healthy controls (HCs). Background Photophobia and allodynia are common in PTH, and there is emerging evidence to support multimodal sensory dysfunction. Methods In this age‐ and sex‐matched cohort study, individuals with PTH (n?=?20) and HCs (n?=?20), aged 18–65 years, were recruited from an institutional database of research volunteers, from the concussion clinic, and via the use of approved flyers posted on the Mayo Clinic Campus in Scottsdale, Arizona. Participants were assessed using the Allodynia Symptom Checklist (ASC‐12), Photosensitivity Assessment Questionnaire (PAQ), State Trait Anxiety Inventory (STAI), and Beck Depression Inventory (BDI). Quantitative sensory testing quantified heat pain thresholds. A light stimulation device quantified light‐induced pain thresholds. Subsequently, heat pain thresholds were obtained immediately, 10, and 40?min after a bright light stressor. Results The mean photophobia symptom severity score, based on the PAQ, was higher in participants with PTH compared with HCs, mean 0.62 (SD?=?0.25) versus mean 0.24 (SD?=?0.24), p?<?0.001. Light‐induced pain thresholds were lower in participants with PTH (median?=?90.5?lux and quartiles?=?17.8 to 378.5) compared with HCs (median?=?863.5?lux and quartiles?=?519.9 to 4906.5) and were independent from BDI and STAI (p?<?0.001). Allodynia scores did not differ between participants with PTH and HCs after adjusting for BDI and STAI scores. Baseline forehead heat pain thresholds were not different, participants with PTH mean 41.9°C (SD?=?0.89) versus HCs mean 44.3°C (SD?=?0.89), p?=?0.061; however, forearm heat pain thresholds were lower in participants with PTH compared with HCs, mean 40.8°C (SD?=?0.80) versus mean 44.4°C (SD?=?0.80), p?=?0.002. The forehead heat pain threshold change from baseline post bright light stressor in participants with PTH versus HCs was different immediately (mean ?1.2 (SD?=?0.53), p?=?0.025), 10?min (mean ?1.8 (SD?=?0.74), p?=?0.015), and 40?min (mean ?1.8 (SD?=?0.88), p?=?0.047). The forearm heat pain threshold change immediately post bright light stressor in participants with PTH versus HCs was different, mean ?1.9°C (SD?=?0.58), p?=?0.001, however, not different at 10 and 40?min. Conclusions Photophobia is higher and light‐induced pain thresholds are lower in participants with PTH. Exposure to a light stressor reduced heat pain thresholds in participants with PTH immediately post bright light stressor, but not in HCs. This study provides evidence for multimodal sensory dysfunction in people with PTH.